Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Schwaz – page 28

373 clinical trials in Schwaz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Schwaz at a glance
373
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

373 trials in Schwaz

Open in trial search

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tilpisertib fosmecarbil
  • Sponsor:Gilead Sciences Inc.

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Endometrial cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Netherton's syndrome

Not recruiting

Study on the Safety and Effectiveness of SXR1096 Cream for Patients with Netherton Syndrome

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:SXR1096
  • Sponsor:Sixera Pharma AB

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Macular oedema+1

Not recruiting

Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Justus-Liebig-Universitaet Giessen

HIV infection

Not recruiting

Study on Switching HIV Treatment to Dolutegravir/Lamivudine in Patients Aged 50+ with Virologic Suppression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Schwaz

What the registry says about research in the country

01 Advanced Breast Cancer Research

Clinical trials focusing on HER2-positive breast cancer treatment, evaluating novel combination therapies with tucatinib, pertuzumab, and trastuzumab for patients with advanced or metastatic disease.

  • Treatment Evaluation
  • Disease Progression Assessment
  • Combination Therapy

Research aims to measure progression-free survival using established evaluation criteria.

02 Targeted Therapy Studies

Investigation of elacestrant plus everolimus in treating patients with specific breast cancer subtypes, particularly focusing on those with estrogen receptor-positive and HER2-negative disease.

  • ESR1-Mutation Research
  • Endocrine Therapy
  • CDK4/6 Inhibitor Studies

Double-blind studies examining effectiveness in patients who have progressed after previous treatments.

03 Precision Medicine Applications

Advanced research incorporating biomarker-driven approaches in breast cancer treatment, with specific focus on hormone receptor status and genetic mutations.

  • Biomarker Analysis
  • Treatment Resistance
  • Personalized Medicine

Studies utilize imaging review committees to ensure accurate assessment of treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.